Outcomes and Barriers to Use of Novel Sickle Cell Therapeutic Agents in a Community Health Center
DOI:
https://doi.org/10.12974/2312-5411.2021.08.1Keywords:
Medication adherence, Community Health Center, Crizanlizumab, SDoH, Sickle cell, Voxelotor.Abstract
Sickle cell disease is genetic red blood cell disorder transmitted via an autosomal recessive mutation due to valine replacing glutamicacid on the beta globulin chain of the hemoglobin molecule. The disease impacts millions of people worldwide majority living in sub-Saharan Africa and India and impacts approximately 100,000 Americans mostly those of African descent. [2-3] In 2019, two novel treatment agents for sickle cell anemia, crizanlizumab (Adakveo) and voxelotor (Oxbryta) were approved by the United States Food and Drug Administration (US FDA) [7, 8]. Both medications offer sickle cell patients improved control of their disease by reducing sickling of the red blood cells (voxelotor) and the painful effects of vaso-occlusive crises, (crizanlizumab). We studied the effects of crizanlizumab and voxelotor on a population of patients in a sickle cell clinic. Fifty-two charts were reviewed for inclusion in the study; 12 patients were using crizanlizumab and 12 patients were using voxelotor. Eight patients met criteria for evaluation of crizanlizumab and 7 patients for voxelotor. Of all data collected, the only significant difference between baseline measures and post-therapy measures was for voxelotor and hemoglobin levels at baseline and at 3 or more months post therapy. This was a small study which reflects the experience of one clinic; sickle cell providers must continue to address the social determinants of health, psychosocial and psychological needs of their patients in addition to prescribing these novel medications.
References
Epstein FH. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 11; 337(11): 762-9. https://doi.org/10.1056/NEJM199709113371107
Zajac M. How Common is sickle cell disease? Sicklecell. com. How Common Is Sickle Cell Disease? (sicklecell. com) Accessed 11/2021
Center for Disease Control and Prevention. Sickle cell disease. Data and statistics on sickle cell disease. https://www.cdc.gov/ncbddd/sicklecell/data.html Accessed 6/11/2021
Ashorobi D, Bhatt R. Bone marrow transplantation in sickle cell disease.
[Updated 2021 May 1]. In: Stat Pearls
[Internet]. Treasure Island (FL): Stat Pearls Publishing; 2021 Jan- Available from: https://www.ncbi.nlm.nih.gov/- books/NBK538515/
Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med 2017; 376(16): 1069-1076 https://doi.org/10.1056/NEJMra1510865
National Center for Advancing Translational Sciences. Genetic and Rare Diseases Information Center. List of FDA Orphan Drugs. https://rarediseases.info.nih.gov/diseases/fda-orphan-drugs Accessed June 11, 2021
US Food and Drug Administration. The FDA encourages new treatments for sickle cell disease. https://www.fda.gov/consumers/consumer-updates/fdaencourages- new-treatments-sickle-cell-disease Accessed June 11,2021
US Food and Drug Administration. FDA approves new treatment for sickle cell disease. https://www.fda.gov/newsevents/ press-announcements/fda-approves-new-treatmentsickle- cell-disease Accessed June 11, 2021
US Food and Drug Administration. FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease. https://www.fda.gov/news-events/pressannouncements/ fda-approves-first-targeted-therapy-treatpatients- painful-complication-sickle-cell-disease
US Food and Drug Administration. FDA approves novel treatment to target abnormality in sickle cell disease. https://www.fda.gov/news-events/press-announcements/fdaapproves- novel-treatment-target-abnormality-sickle-celldisease
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. https://www.nejm.org/toc/nejm/376/5?query=article_issue_lin k N Engl J Med 2017; 376: 429-439 https://doi.org/10.1056/NEJMoa1611770
Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El- Beshlawy A et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med 2019; 381: 509-519 https://doi.org/10.1056/NEJMoa1903212
United States Census Bureau. Quick Facts Dayton city, Ohio. https://www.census.gov/quickfacts/fact/table/daytoncityohio/ RHI225219 Accessed June 11, 2021
Swanson ME, Grosse, SD, Kulkarni R. Disability among individuals with sickle cell disease, literature review from a public health perspective. Am J Prev Med 2011; 41: S390-7. https://doi.org/10.1016/j.amepre.2011.09.006
Adam SS, Flahiff CM, Kamble S, Telen MJ, Reed SD, De Castro LM. Depression, quality of life, and medical resource utilization in sickle cell disease. Blood Adv 2017; 1(23). https://doi.org/10.1182/bloodadvances.2017006940
Castro IPS, Viana MB. Cognitive profile of children with sickle cell anemia compared to healthy controls. J Pediatr (Rio J) 2019; 95(4): 451-457. https://doi.org/10.1016/j.jped.2018.04.012
Wilson-Frederick SM, Hulihan A, Mangum T, Khan M, Geibel, R Malsberger, S et al. Medicaid and CHIP sickle cell disease report, T-MSIS analytic files (TAF) 2017. Baltimore MD: Centers for Medicare and Medicaid Services, 2021
Hasan SP, Hashmi S, Alhassen M, Lawson W, Castro O. Depression in sickle cell disease. J Natl Med Assoc 2003; 95(7): 533-7.
